Table 1.
Summary of reported EV71 neutralizing antibodies.
| Mab Name | Derived from EV71 Genotype | Target | Epitope Type | Epitope Sequence | Remarks |
|---|---|---|---|---|---|
| MAB51 [22] | NUH0083/subgenotype B5 | VP1 | Linear | KQEKD | Able to neutralize all 11 subgenotypes of EV71. Universal neutralizing antibody. |
| 10D3 [23] | 5865/SIN/000009/subgenotype B4 | VP3 | Conformational | Amino acid position 59, 62 and 67 formed the highly conserved knob | Able to neutralize all 11 subgenotypes of EV71. Universal neutralizing antibody. |
| 4E8 [24] | EV71 Hn2 strain/subgenotype C4 | VP1 | Linear | SSKSEYSLVI (aa 240–250); RIYMRMKHVR (aa 250–260) | Neutralization only tested on Hn2 Strain. RIYMRMKHVR epitope is highly conserved among 11 EV71 subgenotypes. SSKSEYSLVI epitope is not highly conserved. |
| 4C6 [24] | EV71 Hn2 strain/subgenotype C4 | VP1 | Linear | SSKSEYSLVI (aa 240–250); RIYMRMKHVR (aa 250–260) | Neutralization only tested on Hn2 Strain. RIYMRMKHVR epitope is highly conserved among 11 EV71 subgenotypes. SSKSEYSLVI epitope is not highly conserved. |
| MAb979 [56] | EV71/subgenotype C2 | VP2 | Linear | Amino acids 136–150, encompasses the exact epitope EDSHP | Neutralizes B4, B5, C2 with cross-reactivity with CVA16. |
| MA28-7 [57] | EV71 strain 1095/subgenotype C2 | VP1 | Conformational | VP1-145 and residues that map to the positively charged patches (VP1-98, VP1-242, and VP1-244) | Neutralizes EV71 subgenotype A, B1, B3, B4 and C2. Neutralizes only specific strains of EV71 that have a conserved glycine at amino acid VP1-145, a surface-exposed residue that maps to the five-fold vertex and that has been implicated in receptor binding. |
| BB1A5 [58] | EV71 strain 52-3/subgenotype C4 | VP2 | Linear | 136-155 (Thr (T141A), Glu (E142A), Ser (S144A) and His (H145A) being the most critical points) | Able to neutralize B3, B4, C2, C4 and C5 subgenogroups. |
| H3B10 [59] | Not known | VP1 | Linear | KQEK (aa 208–222) | Shown capable of neutralizing C2, C4, C5, B4 and B5 subgenogroups. Broad-neutralizing monoclonal antibodies. |
| K8G2 [59] | Not known | VP1 | Linear | KQEK (aa 208–222) | Shown capable of neutralizing C2, C4, C5, B4 and B5 subgenogroups. Broad-neutralizing monoclonal antibodies. |
| 2G8 [60] | EV71 strain AH/08/0 /subgenotype C4 | VP1 | Linear | YPTFGEHKQEKDLEYC | Shown capable of neutralizing C4 subgenogroup. Ala substitutions at Y208, T210, G212, K215, K218, L220, E221, and Y222 could completely abolish or significantly reduce the binding reactivity. |
| 22A12 [61] | EV71 strain 1095/Shiga /subgenotype C2 | VP1 | Linear/Conformational | YPTFGEHKQEKDLEYC (Amino acid residues 211 to 217 of the GH loop are disordered in the procapsid but form a structured loop in the infectious virus. 22A12 recognizes the disordered loop only) | Unable to neutralize infectious virus (native virus). Able to bind to procasid, which protects the live virus from neutralizing antibodies. When being binded to 22A12, the protective shield is lost, hence increasing the neutralizing ability of other antibodies. |
| D2 [62] | Yeast-produced virus-like particles | VP1 | Linear | Not known | Produced by immunizing with yeast-produced virus-like particles rather than whole virus. |
| G12 [62] | Yeast-produced virus-like particles | VP1 | Linear | Not known | Produced by immunizing with yeast-produced virus-like particles rather than whole virus. |
| Mab 22 [63] | EV71 Tainan/4643/98/C2 | VP1 | Conformational | Not known | With neutralization capabilities but no data on the subgenogroups tested. |
| Mab 24 [63] | EV71 Tainan/4643/98/C2 | VP1 | Conformational | Not known | With neutralization capabilities but no data on the subgenogroups tested. |